Last 47 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -0.01 | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 0.01 | 0.58 | 0.28 | 0.20 | 0.12 | 0.06 | 0.17 | 0.24 | 0.19 | 0.21 | 0.32 | 0.21 | 0.13 |
| — | +815.5% | +66.3% | -16.2% | -33.4% | -69.7% | -47.8% | +12.9% | +41.7% | -96.9% | -97.7% | -98.6% | -99.0% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -87.3% | -50.2% | -100.0% | -25.0% | -20.4% | -29.6% | -26.9% | -14.0% | -13.1% | -7.2% | -10.3% | -8.5% | -11.4% |
| — | -70.0% | -271.3% | -78.8% | -55.1% | -310.0% | -160.4% | -64.3% | -14.8% | +3.8% | -49.8% | -33.0% | -47.7% | |
| ROA | -56.6% | -13.1% | -38.4% | -12.8% | -11.8% | -18.7% | -18.3% | -9.9% | -9.4% | -5.2% | -7.6% | -6.4% | -8.6% |
| — | +30.1% | -110.4% | -28.9% | -25.5% | -260.1% | -139.4% | -55.1% | -9.7% | +6.7% | -45.9% | -19.5% | -18.3% | |
| ROIC | -142.7% | -197.9% | -202.4% | -38.2% | -34.7% | -51.8% | -41.4% | -22.1% | -26.2% | -20.5% | -26.6% | -24.7% | -46.2% |
| — | -282.1% | -389.0% | -72.5% | -32.4% | -152.1% | -55.7% | +10.5% | +43.2% | +43.9% | +14.6% | +50.7% | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has weakened 66.3% YoY to 0.90x, tightening the short-term liquidity position. Debt/Equity has risen for 10 consecutive quarters, indicating increasing financial leverage that investors should watch closely.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.08 | 0.41 | 0.27 | 0.18 | 0.08 | 0.07 | 0.07 | 0.06 | 0.05 | 0.05 | 0.05 | 0.05 | 0.03 |
| — | +480.7% | +311.1% | +211.5% | +51.3% | +39.4% | +34.2% | +21.4% | +76.1% | +77.9% | +79.2% | +86.9% | +32.0% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 2.15 | 0.90 | 1.19 | 1.53 | 2.15 | 2.67 | 2.88 | 3.60 | 4.07 | 3.98 | 4.16 | 4.68 | 6.45 |
| — | -66.3% | -58.7% | -57.5% | -47.2% | -32.9% | -30.7% | -22.9% | -36.9% | -0.5% | +0.4% | -13.8% | -66.7% | |
| Quick Ratio | 2.15 | 0.90 | 1.19 | 1.53 | 2.15 | 2.67 | 2.88 | 3.60 | 4.07 | 3.98 | 4.16 | 4.68 | 6.45 |
| — | -66.3% | -58.7% | -57.5% | -47.2% | -32.9% | -30.7% | -22.9% | -36.9% | -0.5% | +0.4% | -13.8% | -66.7% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonTheriva Biologics, Inc.'s current P/E is -0.0x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Theriva Biologics, Inc.'s business trajectory between earnings reports.